A Rare Cause of Antigen Cancer Elevation 125 (CA 125): A Case of Uterine Adenomyosis

In: Women's Health · 2017 · vol. 4(3) · doi:10.15406/mojwh.2017.04.00085 · W2623259720
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View at publisher
AI-generated summary by claude@2026-06, 2026-06-07

This case study investigated isolated uterine adenomyosis associated with elevated CA 125, demonstrating that hormonal treatment influenced the marker's levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Until the recent past, the delays entered the first sign and the diagnosis of adenomyosis was several years. In the absence of a specific sign, its frequency is hardly appreciable because of the great heterogeneity of the studied populations (all on parts of hysterectomy). All research is converging towards reducing the time of diagnosis of adenomyosis and endometriosis. The dosage of CA 125 could be promising. The physiopathology of its synthesis and its secretion shows us that it can be elevated during endometriosis in general, sometimes in the absence of clinical signs. We believe that even in the absence of functional signs, its dosage should be systematic in the presence of uterine pathology even in the absence of endometriosis. We report here a case of isolated adenomyosis (in the absence of any uterine fibroid) associated with an elevation of Ca 125 and whose kinetics of values were influenced by hormonal treatment.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (1)

References (4)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK